dementia-congress-2018-posters-abstracts

3 / 8

Page 33
Notes:
conferenceseries.com
Volume 8 Journal of Alzheimers Disease & Parkinsonism Dementia Congress 2018
September 17-18, 2018
September 17-18, 2018 Singapore
12th World Congress on
Advances and Innovations in Dementia
Jung Yeon Lim et al., J Alzheimers Dis Parkinsonism 2018, Volume 8
DOI: 10.4172/2161-0460-C5-049
Potential application of human neural crest-derived nasal stem cells in models of Alzheimer’s
disease as a clinically applicable therapy
Jung Yeon Lim, Sang In Park, Soon A Park and Sung Won Kim
The Catholic University of Korea, Republic of Korea
Potential application of human neural crest-derived nasal stem cells in models of Alzheimer’s disease as a clinically applicable
therapy: Stem cell transplantation is a promising therapeutic strategy for the treatment of many neurological disorders.
The therapeutic effects, however, are sometimes inconsistent and unpredictable. Human Neural Crest-Derived Nasal Stem
Cells (hNCNSCs) are an excellent alternative source of adult stem cells for clinical use because they can be obtained easily
by minimally invasive collection procedures and expanded rapidly ex vivo for transplantation. Moreover, the characteristics
of hNCNSCs, including their proliferation, differentiation and immunophenotype are not affected by donor age or passage
number, while other kinds of stem cells exhibit age and passage-related reduction in multiple characteristics. In the present
study, we investigated its potential for treatment of Alzheimer’s Disease (AD) in comparison with Human Bone Marrow-
Derived Mesenchymal Stem Cells (hBMSCs), which is the most commonly used cell type for regenerative medicine. Here,
hNCNSCs is protective against amyloid-β peptide (Aβ1-42) toxicity in culture of human Neural Stem Cells (hNSCs). Likewise,
in a transgenic mouse model of AD, transplantation of hNCNSCs greatly reduces the levels of Aβ42, plaque formation and
inflammatory microglia expression, concomitant with increased survival of hippocampal and cortex neurons when compared
with transplantation of hBMSCs. In addition, hNCNSCs showed better cell survival and greater inhibition in Aβ1-42-induced
up-regulation of the BDNF pro-domain and their receptor p75NTR in a mouse brain of AD. These results suggest that the
potential application of hNCNSCs of future treatment for patients with AD.
Biography
Jung Yeon Lim has completed her PhD from Department of Neurobiology, The Catholic University of Korea and Postdoctoral studies from the Catholic University of
Korea and University of Cambridge, UK. She is a Research Professor in Postech-Catholic Biomedical Engineering Institute, The Catholic University of Korea. She
was mainly involved in numerous publications relating to high performance stem cells therapy for treatment of serious neurological diseases such as strokes, spinal
cord injury and Alzheimer’s disease. Moreover, she has investigated the function of the nerve support factor called BDNF and its possible role in Alzheimer’s disease.